Cancer is becoming more common. Additionally, leading firms focused on product approval are projected to drive the global CAR T cell treatment market throughout the projection period. The negative effects of CAR T cell treatment are a key issue impeding the growth of the global CAR T cell therapy market. The market's leading players are predicted to employ more inorganic methods such as agreement. The rising use of inorganic methods like agreement by the industry's leading players is likely to fuel market growth during the forecast period. The rising cancer prevalence is likely to fuel market expansion throughout the forecast period.
According to Coherent Market Insights, Global CAR T Cell Therapy Market is estimated to be valued at US$ 2,259.5 million in 2022 and is expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030).
Key Companies in the CAR T Cell Therapy Industry:
1. Bristol-Myers Squibb Company
The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. ristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. In June 2022, Bristol-Myers Squibb Company, one of the global leader in Biopharmaceutical company, obtained the U.S. Food and Drug Administration (FDA), approval for Breyanzi CAR T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after one prior therapy. Approval was based on data from the Phase 2 pilot company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL.
2. Johnson & Johnson Services, Inc.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. In February, 2022, Johnson & Johnson Services, Inc., one of the largest healthcare company, announced that, the U.S. Food and Drug Administration approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.
3. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. In December 2021, Novartis AG, one of the global healthcare company, introduced T-Charge next-generation CAR-T platform which serve as the foundation for various new investigational CAR-T cell therapies at American Society of Hematology Annual Meeting & Exposition (ASH) 2021.
4. CARsgenTherapeutics Co.,Ltd
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. Founded in 2014. Headquartered in Shanghai, China. On February 2022, CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production. CARsgen has received the Certificate of Compliance from the City-County Inspections Department of Durham, enabling CARsgen to advance to clinical manufacturing.
5. Aurora Biopharma
Aurora Biopharma is a clinical stage company founded on a single mission to revolutionize the treatment of cancer, by using the human body’s immune system. Aurora is developing state-of-the-art cancer immunotherapy, a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T cells therapy. Aurora BioPharma is located in Cambridge, Massachusetts, United States. Founded in 2015.
6. Legend Biotech
Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization. Founded in 2014, headquartered in New Jersey, U.S.
7. Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Gilead Sciences is located in Foster City, California, United States, founded in 1987.
8. Pfizer Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide.
9. Sorrento Therapeutics, Inc.
Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The company was founded in 2006, headquartered in California. U.S.
*Definition- Chimeric antigen receptor (CAR)-T cell therapy is a sort of gene cell therapy that uses T lymphocytes to attack cancer cells. CAR T cell treatment consists of three steps: collection of T cells, engineering of T cells, and infusion of CAR T cells into the human body.
